Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...

Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.